International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2023
September 26 and 27
Welcome
We are pleased to announce that the 14th edition of the International Workshop on Clinical Pharmacology of Tuberculosis Drugs will take place 26-27 September 2023 as a virtual meeting.
This abstract-driven workshop has been the leading annual meeting in the tuberculosis (TB) pharmacology field since 2008. The aim of the meeting is to contribute to the optimization of TB treatment by providing an independent platform for presentation and discussion of the latest scientific developments in the TB pharmacology field.
This year we are excited to broaden the audience for this workshop. If you work in the field of TB, you are invited to join us. This includes preclinical and clinical pharmacology researchers from academia and industry; medical doctors, pharmacists and pharmacologists involved in clinical management of TB patients; laboratorians, nurses, PhD students; and representatives from regulatory or non-governmental organizations active in the TB-field.
The program consists of state-of-the-art lectures by selected invited experts, combined with oral and e-poster abstract presentations. The workshop is informal in setting and is meant to be highly interactive.
We look forward to seeing you virtually this September!
On behalf of the Organizing Committee,
Virtual Meeting, 26-27 September, 2023
| Lectures | Speakers | Presentations | Abstracts | Posters |
| DAY 1 Tuesday 26 September | ||||
| Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | ||||
| Chairs: Helen McIlleron & Eric Nuermberger | ||||
| Invited lecture. New oxazolidinones: lessons learned about sutezolid and delpazolid | Norbert Heinrich | |||
| Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis | Simon Koele | Abstract | ||
| TBAJ-587 and ERA4TB: a productive clinical development partnership | Almari Conradie | Abstract | ||
| Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis | Ralf Stemkens | Abstract | ||
| Delpazolid population pharmacokinetics in patients with pulmonary tuberculosis | Isabella van der Feltz | Abstract | ||
| Session 2 Patient populations: pharmacological aspects of specific forms of TB | ||||
| Chairs: Jerry Nedelman & Ulrika Simonsson | ||||
| Invited lecture. Insights on TB meningitis treatment from animal models and advanced imaging techniques | Sanjay Jain | |||
| Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of multidrug-resistant tuberculosis in Indonesia | Vycke Yunivita & Fajri Gafar | Abstract | ||
| The association between drug exposure, susceptibility and response and clinical thresholds for pyrazinamide in MDR-TB treatment | Shulan Dong | Abstract | ||
| Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy | Manna Semere Gebreyesus | Abstract | ||
| Effect of pregnancy on population pharmacokinetics of levofloxacin in South African adults with rifampicin-resistant tuberculosis | Sharon Sawe | Abstract | ||
| Session 3 Short presentations & pitches for poster viewing | ||||
| Chair: Geraint Davies | ||||
| Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations | Budi Octasari Susanto | Abstract | ||
| A study of the drug interaction potential of TBAJ-876 on CYP3A4 and P-gp substrates in healthy adults | Jerry Nedelman | Abstract | Poster | |
| Pharmacokinetics of levofloxacin during pregnancy and post-partum in persons living with HIV and without HIV and receiving treatment for rifampicin-resistant | Jennifer Hughes | Abstract | Poster | |
| Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis | Noha Abdelgawad | Abstract | Poster | |
| Population pharmacokinetic modelling of pyrazinamide in plasma and cerebrospinal fluid from HIV-associated tuberculosis meningitis adults | Jose Miguel Calderin | Abstract | Poster | |
| Limited sampling strategy and dose evaluation for second-line anti-tuberculosis drugs in patients with type II diabetes mellitus | Jiayi Cao | Abstract | Poster | |
| Evaluating two strategies for the design of pediatric pharmacokinetic studies | Yuanxi Zou | Abstract | Poster | |
| DAY 2 Wednesday 27 September | ||||
| Session 4 The role of consortia in TB drug development | ||||
| Chairs: Rob Aarnoutse & Charles Peloquin | ||||
| ERA4TB | Santiago Ferrer Bazaga | |||
| Unite4TB | Martin Boeree | |||
| PAN-TB | Charles Wells | |||
| Panel discussion on preselected topics & propositions | Coming Soon | |||
| Session 5 Approaches and tools in TB drug development and optimization and in treatment of patients | ||||
| Chairs: Susan Swindells & Paolo Denti | ||||
| Higher-order combination drug regimens and pharmacodynamic markers of response in a mouse tuberculosis infection model | Michael Lyons | Abstract | ||
| Power to identify exposure-response relationships in phase IIa tuberculosis trials with multi-dimensional bacterial load modeling | Simon Koele | Abstract | ||
| Development of a PBPK model for TBAJ-876 within the SIMCYP population-based simulator and subsequent evaluation of DDI liability as a victim of CYP3A4 | Ludwig Vincent | Abstract | ||
| Drug-drug interaction management of bedaquiline and other medications associated with QT-interval prolongation | David Burger | Abstract | ||
| Rifampin dosing and pharmacokinetics from an international TDM service, 2022 | Nicole Maranchick | Abstract | ||
| Saliva-based assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer | Ricky Chen | Abstract | ||
| Session 6 Short presentations & pitches for poster viewing | ||||
| Chair: Jerry Nedelman | ||||
| Co-crystals for tuberculosis | Shagun Gogna | Abstract | Poster | |
| 4β-hydroxycholesterol-to-cholesterol ratio as an endogenous biomarker in human plasma to determine treatment effects of induction and inhibition of CYP3A4 | Yashara Ryan | Abtract | Poster | |
| Population pharmacokinetics of pretomanid in participants of a randomised controlled clinical trial for rifampicin-resistant tuberculosis | Bern-Thomas Nyang'wa | Abstract | Poster | |
| Population pharmacokinetics of clofazimine in a randomised controlled clinical trial for rifampicin-resistant tuberculosis | Ilaria Motta | Poster | ||
| Physico-chemical properties influencing penetration into saliva: a systematic review | Anh Thi Nguyen | Abstract | Poster | |
| Analysis of time to positivity of Mycobacterium tuberculosis in response to treatment for drug susceptible tuberculosis in South African patients | Marie Wijk | Abstract | Poster | |